Szacuje si, e potencjalne skutki uboczne obejmuj bl i zaczerwienienie, ble gowy, nudnoci i zawroty gowy
Chong B, Jayabaskaran J, Ruban J, Goh R, Chin YH, Kong G, et al
In three nested casecontrol studies from England and Wales, involving 440,089 patients with T2DM and without ASCVD treated with non-insulin glucose-lowering medication, combined SGLT2i and GLP-1RA therapy used for primary prevention was associated with 30% lower odds of MACE (defined as myocardial infarction/acute coronary syndrome, stroke/transient ischemic attack, and/or cardiovascular death) compared with other combination regimens (OR, 0.70
A: A pre-treatment medical consultation is mandatory to determine if you are a suitable candidate and to tailor the therapy to your specific needs
2025 was quite a year
Smart et al., 2007)